Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18,079 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients.
Liu J, Zhao S, Yang C, Ma L, Wu Q, Meng X, Zheng B, Guo C, Feng K, Shang Q, Liu J, Wang J, Zhang J, Shan G, Xu B, Liu Y, Ying J, Wang X, Wang X. Liu J, et al. Among authors: xu b. Chin Med J (Engl). 2023 Jan 20;136(2):184-193. doi: 10.1097/CM9.0000000000002411. Chin Med J (Engl). 2023. PMID: 36921106 Free PMC article.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, Xu W, Liu T, Xu B, Wang X, Gao SJ, Zhang HL, Hu Y, Li Y, Cheng Y, Yang HY, Cao JN, Zhu ZM, Hu JD, Zhang W, Jing HM, Ding KY, Zhang XY, Zhao RB, Zhang B, Tian YM, Song YP, Song YQ, Zhu J. Deng LJ, et al. Among authors: xu b, xu w. Blood Adv. 2023 Aug 22;7(16):4349-4357. doi: 10.1182/bloodadvances.2022009168. Blood Adv. 2023. PMID: 37078706 Free PMC article. Clinical Trial.
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
Gao Y, Huang Y, Zhang Q, Yang H, Li Y, Li Y, Zhou M, Yang R, Xu B, Liu L, Yang Y, Peng Z, Yu D, Zhou H, Zhang R, Zhang H, Qi J, Xi Y, Xing X, Wang Z, Jing H, Shuang Y, Zhang X, Ma L, Jin H, Lin L, Li C, Xue J, Liu Y, Yuan J, Huang H. Gao Y, et al. Among authors: xu b. Cancer. 2025 Jan 1;131(1):e35672. doi: 10.1002/cncr.35672. Cancer. 2025. PMID: 39748491 Free PMC article. Clinical Trial.
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.
Zha J, Chen Q, Zhang W, Jing H, Ye J, Liu H, Yu H, Yi S, Li C, Zheng Z, Xu W, Li Z, Lin Z, Ping L, He X, Zhang L, Xie Y, Chen F, Sun X, Su L, Zhang H, Yang H, Zhao W, Qiu L, Li Z, Song Y, Xu B. Zha J, et al. Among authors: xu b, xu w. Biomark Res. 2025 Jan 3;13(1):2. doi: 10.1186/s40364-024-00716-4. Biomark Res. 2025. PMID: 39754201 Free PMC article.
Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase Ⅱ YH-S001-04 clinical trial.
Kan S, Bai H, Liu H, Cui J, Ke X, Zhang H, Liu L, Yan D, Jiang Y, Zang A, Qi J, Wang L, Liu Z, Xu B, Zhang Y, Zhang Z, Zhao X, Hu C, Yang S, Zhou H, Shi J, Shao Z, Xiang Y, Lin N, Zhang M. Kan S, et al. Among authors: xu b. Leuk Res. 2024 Nov 26;149:107633. doi: 10.1016/j.leukres.2024.107633. Online ahead of print. Leuk Res. 2024. PMID: 39799811
18,079 results
You have reached the last available page of results. Please see the User Guide for more information.